Agaton

Agaton is a Swedish biotechnology company that operates a high-throughput protein production platform, originally established as the manufacturing arm of the Human Protein Atlas (HPA) project. The company focuses on the design, production, and validation of recombinant protein fragments known as Protein Epitope Signature Tags (PrESTs), which serve as precise antigens for antibody production and mass spectrometry standards. By mapping and producing fragments for nearly the entire human proteome, Agaton provides critical infrastructure for proteomics research, drug target discovery, and clinical diagnostics. Following its acquisition by Atlas Antibodies in 2021, the company integrated its specialized production facilities to support the commercialization of high-quality research reagents. Agaton’s platform remains a cornerstone of large-scale protein research, facilitating proteome-wide studies across various therapeutic areas including oncology and neurology. The company's automated pipelines ensure consistency and high-fidelity validation, making them a preferred partner for global proteomics initiatives.